YM-53601 (Standard)

CAT: 0804-HY-100313ARSize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-100313ARSize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
YM-53601 (Standard) is the analytical standard of YM-53601 (HY-100313A) . This product is intended for research and analytical applications. YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo[1]. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent[2]. YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation[3].
CAS Number
[182959-33-7]
Target
Farnesyl Transferase; HCV; Reference Standards
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Others
Field of Research
Infection; Metabolic Disease
Smiles
F/C(COC1=CC(NC2=C3C=CC=C2)=C3C=C1)=C4CN5CCC/4CC5.[H]Cl
Molecular Formula
C21H22ClFN2O
Molecular Weight
372.86
References & Citations
[1]T Ugawa, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol. 2000 Sep;131 (1) :63-70. |[2]Tsukasa Ishihara, et al. Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. Bioorg Med Chem. 2003 Aug 15;11 (17) :3735-45. |[3]Eun-Mee Park, et al. Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation. FEBS Lett. 2014 May 2;588 (9) :1813-20. |[4]Joan Montero, et al.Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008 Jul 1;68 (13) :5246-56.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Popular Products